AU1522101A - Heparanase inhibitors for the treatment of heart failure - Google Patents

Heparanase inhibitors for the treatment of heart failure

Info

Publication number
AU1522101A
AU1522101A AU15221/01A AU1522101A AU1522101A AU 1522101 A AU1522101 A AU 1522101A AU 15221/01 A AU15221/01 A AU 15221/01A AU 1522101 A AU1522101 A AU 1522101A AU 1522101 A AU1522101 A AU 1522101A
Authority
AU
Australia
Prior art keywords
treatment
heart failure
heparanase inhibitors
heparanase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU15221/01A
Inventor
Alfred Hahn
Dieter Herr
Volker Laux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Publication of AU1522101A publication Critical patent/AU1522101A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU15221/01A 1999-11-19 2000-11-17 Heparanase inhibitors for the treatment of heart failure Abandoned AU1522101A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19955803A DE19955803A1 (en) 1999-11-19 1999-11-19 Use of heparanase inhibitors for the treatment of cardiac insufficiency
DE19955803 1999-11-19
PCT/EP2000/011441 WO2001035967A1 (en) 1999-11-19 2000-11-17 Heparanase inhibitors for the treatment of heart failure

Publications (1)

Publication Number Publication Date
AU1522101A true AU1522101A (en) 2001-05-30

Family

ID=7929687

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15221/01A Abandoned AU1522101A (en) 1999-11-19 2000-11-17 Heparanase inhibitors for the treatment of heart failure

Country Status (4)

Country Link
EP (1) EP1229921A1 (en)
AU (1) AU1522101A (en)
DE (1) DE19955803A1 (en)
WO (1) WO2001035967A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2453566A1 (en) * 2001-07-13 2003-01-23 Imclone Systems Incorporated Method and composition for inhibiting heparanase activity
PT1427427E (en) 2001-09-12 2011-09-13 Sigma Tau Res Switzerland Sa Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
DE10258770B4 (en) * 2001-12-18 2005-02-10 F. Hoffmann-La Roche Ag Test for inhibitors of heparanase, useful for treatment of e.g. cancer and inflammatory disease, using immobilized, labeled heparanase substrate
CH696701A5 (en) 2001-12-18 2007-10-15 Hoffmann La Roche A method for testing an agent for its ability to inhibit heparanase activity.
GB0218147D0 (en) * 2002-08-05 2002-09-11 Oxford Glycosciences Uk Ltd Novel compounds
EP1479764A1 (en) 2003-05-19 2004-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Heparanase-derived peptides for vaccination of tumor patients

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996008559A1 (en) * 1994-09-16 1996-03-21 Cardiac Crc Nominees Pty. Ltd. Glycosaminoglycan-degrading enzyme inhibition and resultant disease therapies
WO1999023214A1 (en) * 1997-10-30 1999-05-14 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing cardiac contractility mediated by myocyte p2 purinoceptors and models thereof
WO1999043830A2 (en) * 1998-02-24 1999-09-02 Pharmacia & Upjohn Company Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity

Also Published As

Publication number Publication date
WO2001035967A1 (en) 2001-05-25
DE19955803A1 (en) 2001-05-23
EP1229921A1 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
AU3920900A (en) Compounds and methods to treat cardiac failure and other disorders
AU5032500A (en) Treatment of irregular ventricular contractions
AU2002218742A1 (en) Application of photochemotherapy for the treatment of cardiac arrhythmias
AU3791601A (en) Treatment of coal
AU6530600A (en) Use of neurotoxin for treating cardiac muscle disorders
AU2001284413A1 (en) Medicinal compositions for preventing or treating heart failure
AU6910600A (en) Methods for the treatment of mental disorders
AU5779800A (en) Therapy-selection methods for implantable heart monitors
AU8026200A (en) Treatment of heart disease with cox-2 inhibitors
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
AU4364400A (en) Azaindole derivatives for the treatment of depression
AU2003233820A1 (en) Method for the treatment of starch
AU2002249947A1 (en) Inhibition of protein-phosphatases for the treatment of heart failure
AU1522101A (en) Heparanase inhibitors for the treatment of heart failure
AU1878201A (en) Composition for the treatment of damaged tissue
AU7750100A (en) Method for the treatment of obesity
AU7106300A (en) Treatment of skin disorders
SI1534296T1 (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
AU7653600A (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
HU0001891D0 (en) Medicament for the treatment of migraine
AU3501100A (en) Synergistic combination for treatment of viral-mediated diseases
AU1618901A (en) Treatment of rosacea
AU4598400A (en) Method of treatment
AU2683500A (en) Compositions for the treatment of pain
AU4920200A (en) Compositions for the preserving treatment of feeds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase